Supplementary Table from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis

MLA

Luis de la Cruz-Merino, et al. Supplementary Table from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.22487339.

APA

Luis de la Cruz-Merino, Antonio Rueda-Domínguez, Victor Sánchez-Margalet, Maria Casanova-Espinosa, Tomás Álvaro-Naranjo, Lejeune Marylene, Marta Navarro, Margarita Sánchez-Beato, Mariano Provencio-Pulla, Isabel Fernández-Román, Pablo Espejo-García, Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, María Guirado-Risueño, Jorge Labrador, Laura Gálvez-Carvajal, Delvys Rodríguez-Abreu, Antonio Salar-Silvestre, José Gómez-Codina, … Natalia Palazón-Carrión. (2023). Supplementary Table from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis. https://doi.org/10.1158/1078-0432.22487339

Chicago

Luis de la Cruz-Merino, Antonio Rueda-Domínguez, Victor Sánchez-Margalet, Maria Casanova-Espinosa, Tomás Álvaro-Naranjo, Lejeune Marylene, Marta Navarro, et al. 2023. “Supplementary Table from Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis,” March. doi:10.1158/1078-0432.22487339.